### SANGAMO BIOSCIENCES INC Form SC 13G/A February 14, 2003

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 3)\*

Sangamo Biosciences, Inc.
 (Name of Issuer)

Common Stock (Title of Class of Securities)

800677106 (CUSIP Number)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP NO. 800677106

NAME OF REPORTING PERSONS.
 I.R.S. IDENTIFICATION NO'S. OF ABOVE PERSONS (ENTITIES ONLY).

Stephens Group, Inc.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) [ ]

(b) [ ]

	_aga: 1 milg: 0/ 11 ta/ 11 to 2/ 0001_110_20 m					
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Arkansas, USA					
Number of Shares Beneficially Owned by Each Reporting Person With:						
5.	SOLE VOTING POWER	1,587,783				
6. 7.	SHARED VOTING POWER SOLE DISPOSITIVE POWER	28,290 1,587,783				
8.	SHARED DISPOSITIVE POWER	28,290				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	1,616,073				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9 EXCLUDES CERTAIN SHARES	[ ]				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	6.6%				
12.	TYPE OF REPORTING PERSON	НС				
SCHEDULE 13G						
	0. 800677106					
1.	NAME OF REPORTING PERSONS.  I.R.S. IDENTIFICATION NO'S. OF ABOVE PERSONS (ENTITIES ONLY).					
Stephens-Sangamo Biosciences, LLC						
2.	· · · ·		(a) [ ] (b) [ ]			
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Arkansas, USA					
Number of Shares Beneficially Owned by Each Reporting Person With:						
5.	SOLE VOTING POWER	1,587,783				
6. 7.	SHARED VOTING POWER SOLE DISPOSITIVE POWER	-0- 1,587,783				
8.	SHARED DISPOSITIVE POWER	-0-				

	EACH REP	ORTING PE	ERSON	1,587,783			
10.		X IF THE CERTAIN	AGGREGATE AMOUNT IN ROW (9) SHARES	[ ]			
11.	PERCENT ROW (9)	OF CLASS	REPRESENTED BY AMOUNT IN	6.5%			
12.	TYPE OF	REPORTING	G PERSON	00			
CUSIP NO. 800677106							
ITEM 1.	(a)	Name of	Issuer: Sangamo Bioscience	es, Inc.			
	(b)	Address	of Issuer's Principal Execu	tive Offices:			
			501 Canal Boulevard, Suite Richmond, CA 94804	A100			
ITEM 2.	(a)	Name of	-	Group, Inc. Sangamo Biosciences, LLC			
	(b)	Address	of Principal Business Office	e or, if none, Residence			
			111 Center Street Little Rock, Arkansas 722	01			
	(c)	Citizens	ship: Arkansas, USA				
	(d) Title of Class of Securities: Common Stock						
	(e)	CUSIP Nu	umber: 800677106				
ITEM 3.			STATEMENT IS FILED PURSUANT .3D-2(b) OR (c), CHECK WHETH:				
ITEM 4.	OWNERSHIP. PROVIDE THE FOLLOWING INFORMATION REGARDING THE AGGREGATE NUMBER AND PERCENTAGE OF THE CLASS OF SECURITIES OF THE ISSUER IDENTIFIED IN ITEM 1.						
(a)	Amount beneficially owned: 1,616,073						
(b)	Percent of class: 6.6%						
(C)	Number of shares as to which the person has:						
	(i) So	le power	to vote or to direct the vo	1,587,783			

(ii) Shared power to vote or to direct the vote: 28,290

(iii) Sole power to dispose or to direct the disposition of: 1,587,783

(iv) Shared power to dispose or to direct the disposition of: 28,290

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

N/A

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Stephens-Sangamo Biosciences, LLC is an investment LLC of which Stephens Group, Inc. is the manager. Stephens Group, Inc. and the following individuals and entities are members of the LLC:

Warren A. Stephens Trust UID 9/30/87 Harriet Calhoun Stephens Trust UID 3/22/84 Warren A. Stephens Grantor Trust UID 9/30/87 Grandchild's Trust #2 Bess C. Stephens Family Trust UID 1/4/85 W. R. Stephens, Jr. Revocable Trust UID 2/19/93 W. R. Stephens, Jr. Children's Trust UID 3/1/95 MAM Holdings, International, Inc. Pamela Diane Stephens Trust One UID 4/10/92 Stephens Investment Partners III LLC Jacoby Enterprises, Inc. J and J Partners Curtis F. Bradbury Douglas H. Martin Douglas H. Martin IRA Martin Family Partnership III C. Ray Gash IRA Robert L. Schulte K. Rick Turner K. Rick Turner IRA Robert Janes Jackson Farrow Jr. IRA William S. Walker Gordon & Amanda Grender, jtwros Andrew Stafford-Deitsch Steve Goldman Frank Lorge Berry Summerour Jason Zhang

The number of shares reported as being owned by Stephens Group, Inc. also includes the ownership by Stephens Inc., its second-tier subsidiary, of 200 shares of the common stock of Sangamo Biosciences, Inc. ("SGMO") for its own account and 28,090 shares held in discretionary

accounts for clients. In addition to the shares reported in Item 4, principals of Stephens Group, Inc. own 235,212 shares of SGMO common stock. Stephens Group, Inc. has no voting power or dispositive power over such shares and disclaims beneficial ownership of these shares.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. N/A

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP N/A

ITEM 9. NOTICE OF DISSOLUTION OF GROUP N/A

ITEM 10. CERTIFICATION.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2003
---Date

Stephens Group, Inc. and Stephens-Sangamo Biosciences, LLC

By: /s/ David A. Knight
----David A. Knight

Vice President of Stephens Group, Inc.